Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001214531 | SCV001386215 | benign | Epileptic encephalopathy | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001844273 | SCV002103779 | uncertain significance | not specified | 2022-02-01 | criteria provided, single submitter | clinical testing | Variant summary: GABBR2 c.1364C>A (p.Thr455Asn) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251328 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in GABBR2 causing Early Infantile Epileptic Encephalopathy 59 (4e-05 vs ND), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1364C>A in individuals affected with Early Infantile Epileptic Encephalopathy 59 and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |